Definium Therapeutics (DFTX) Assets Average (2022 - 2026)

Definium Therapeutics (DFTX) has 5 years of Assets Average data on file, last reported at $420.7 million in Q1 2026.

• Assets Average for Q1 2026 came in at $420.7 million, up 45.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $420.7 million (up 45.7% YoY), and the FY2025 annual result was $371.1 million, up 73.95% from the prior year.
• Assets Average climbed to $420.7 million in Q1 2026 per DFTX's latest filing, from $338.5 million in the prior quarter.
• Over five years, Assets Average peaked at $420.7 million in Q1 2026 and troughed at $133.0 million in Q4 2023.
• A 5-year average of $227.3 million and a median of $200.0 million in 2024 frame the typical range for Assets Average.
• The sharpest annual moves came in 2023 and 2024: Assets Average fell 24.17% in 2023, then soared 133.72% in 2024.
• A 5-year view of Assets Average shows it stood at $175.4 million in 2022, then slipped by 24.17% to $133.0 million in 2023, then soared by 133.72% to $311.0 million in 2024, then grew by 8.86% to $338.5 million in 2025, then increased by 24.28% to $420.7 million in 2026.
• Business Quant data shows DFTX's Assets Average at $420.7 million in Q1 2026, $338.5 million in Q4 2025, and $251.0 million in Q3 2025.